Clinical Trials Directory

Trials / Completed

CompletedNCT00483990

Phase I Study of PSD502 (Lidocaine Prilocaine Spray) Applied to the Glans Penis up to Three Times a Day for 21 Days in Healthy Male Volunteers

A Phase I, Double-blind, Stratified, Parallel Group, Placeob-controlled Study of the Safety, Tolerability and Pharmacokinetics of PSD502 (Lidocaine Prilocaine Spray) Applied to the Glans Penis up to Three Times Daily for 21 Days in Healthy Male Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
16 (planned)
Sponsor
Plethora Solutions Ltd · Industry
Sex
Male
Age
18 Years
Healthy volunteers
Accepted

Summary

The main objective of the study is to determine the safety and tolerability of repeated application of PSD502 to the glans penis in healthy male volunteers

Detailed description

This is a phase I, double-blind, stratified, parallel group, placebo-controlled repeat dose study in a minimum of 8 circumcised and 8 uncircumcised healthy male volunteers. Subjects will attend 2 study visits, of which 1 will be a Screening Visit (Visit 1) and the other, a consecutive 21-day treatment visit (Visit 2; Days 1-21) which commences no more than 14 days after the Screening visit. Subjects will reside in the phase I unit throughout the treatment period. The duration of each subject's participation in the study will be up to 5 weeks. Subjects are stratified based on whether they are circumcised or uncircumcised and within each stratified group subjects are randomized to PSD502 (lidocaine prilocaine spray) or placebo in a 3:1 ratio. Procedures during the 21 day treatment period include: visual examination of the glans penis, blood sample collection for pharmacokinetic analysis of lidocaine and prilocaine, swabbing of the glans penis for residual PSD502, vital signs and 12-lead ECG, adverse event enquiries and collection of concomitant medications. Subjects are discharged from the clinic on Day 21 following a safety evaluation.

Conditions

Interventions

TypeNameDescription
DRUGPSD502

Timeline

Start date
2007-03-01
Primary completion
2007-06-01
Completion
2007-06-01
First posted
2007-06-08
Last updated
2010-07-15

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00483990. Inclusion in this directory is not an endorsement.